FIELD: biotechnology.
SUBSTANCE: present invention relates to the field of biotechnology, specifically derivatives of epidermal growth factor (EGF(A)-like domain of a receptor of low density lipoprotein (R-LDL) receptor, and can be used in medicine. The invention makes it possible to obtain a stable conjugate of a wild-type peptide analog of EGF(A) (P-LDL(293-332)) with at least one lipophilic substituent-a derivative of an organic fatty acid
EFFECT: present invention can be applied in treatment of cardiovascular diseases and a number of metabolic diseases, for example, to reduce cholesterol levels or to treat dyslipidemia.
22 cl, 3 dwg, 15 tbl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| SELECTIVE COMPOUNDS OF YY PEPTIDE AND USE THEREOF | 2016 |
|
RU2726777C2 |
| STABLE PROTRACTED GLP-1/GLUCAGON RECEPTOR CO-ANTAGONISTS FOR MEDICAL USE | 2014 |
|
RU2683039C2 |
| NOVEL GLUCAGON ANALOGUES | 2011 |
|
RU2559320C2 |
| FGF21 DERIVATIVES AND USE THEREOF | 2015 |
|
RU2729011C2 |
| NOVEL GLUCAGON ANALOGUES | 2012 |
|
RU2610175C2 |
| DOUBLE ACYLATED GLP-1 DERIVATIVES | 2012 |
|
RU2602601C2 |
| POLYPEPTIDES | 2012 |
|
RU2669999C2 |
| SOLID COMPOSITIONS FOR ORAL ADMINISTRATION | 2018 |
|
RU2777206C2 |
| ANTIBODY AND DRUG CONJUGATES (ADC) AND ANTIBODY AND PRODRUG CONJUGATES (APDC) CONTAINING ENZYMATICALLY CLEAVABLE GROUPS | 2016 |
|
RU2751512C2 |
| INSULIN CONJUGATES | 2019 |
|
RU2809189C2 |
